AI future tech, longevity science, and reverse aging. Tracking the signals reshaping human life.
Joined September 2021
- Tweets 87
- Following 23
- Followers 13
- Likes 214
1 Photos and videos
Jun 10
Longevity is not only “reverse aging.” It is also prevention that lasts.
Scribe has clearance to test STX-1150 in humans: a one-dose approach designed to silence PCSK9, lower LDL cholesterol, and avoid permanent DNA editing.
If safe, this is programmable prevention for heart disease risk.
scribetx.com/news/scribe-the…
10
Jun 10
The headline sounds sci-fi: the first “reverse-aging” shot has reached a human.
The real signal is narrower but bigger: scientists are testing whether old cells can be reprogrammed enough to treat age-related disease.
First target: vision loss. Not immortality. Not proven yet. But a real human test.
businessinsider.com/first-ev…
10
Jun 10
Are we closer to curing cancer? The honest ASCO 2026 signal is not “one cure.” It is more time, fewer blind guesses.
A pancreatic-cancer pill doubled median survival in a major trial. Other tools may help expose hidden tumors or let some patients safely skip chemo.
theguardian.com/science/2026…
1
26
Jun 9
Reverse-aging science just crossed a real line: first human dosing.
Life Biosciences says the first participant has received ER-100, an epigenetic restoration therapy for optic nerve diseases like glaucoma and NAION.
Plain English: this is not immortality, and not proof yet. Phase 1 is mainly about safety.
But it is a major signal: cellular rejuvenation is moving from animals into humans.
Source:
lifebiosciences.com/life-bio…
1
20
Jun 9
Why hasn't AI already “solved biology” the way it writes code?
Anthropic's new research points to a boring but huge bottleneck: biology data is messy, scattered, and hard for agents to retrieve reliably.
Plain English: better models matter. But cancer, aging, outbreak response, and drug discovery also need machine-readable biology infrastructure.
That is how AI moves from impressive demos to dependable science.
Source:
anthropic.com/research/agent…
14
Jun 9
Pancreatic cancer is where “more time” matters most.
Tango says vopimetostat daraxonrasib produced a 92% response rate in 12 evaluable metastatic PDAC patients, with 90% progression-free at 6 months.
Plain English: tumor shrinkage is not a cure. But if Phase 3 confirms this, one of the hardest cancers may become more controllable.
Source:
tangotx.gcs-web.com/news-rel…
36
Jun 9
The next AI frontier may be biology, not another chatbot.
Bezos, Nvidia/Lilly, Isomorphic, Retro and NewLimit all point to the same signal: serious money is moving toward programmable biology and longer healthy life.
Not reverse aging yet. But the direction is clear.
Source: Global Economic / Kim Joo-won
m.g-enews.com/article/Global…
12
Jun 8
Everyone wants the same thing from future medicine: more time.
UCLA reports an investigational daily pill nearly doubled median survival in previously treated metastatic pancreatic cancer: 13.2 months vs 6.7 months with chemotherapy.
Plain English: not a cure. But in one of the deadliest cancers, a survival signal like this matters.
This is the kind of real-world outcome AI biology should help accelerate.
Source:
newsroom.ucla.edu/releases/i…
18
Jun 8
The rich are not just funding better apps. They are funding more healthy years.
Retro Biosciences, the Sam Altman-backed longevity company, says its new round values it at $1.8B.
Its stated mission: add 10 healthy years to human lifespan.
Plain English: this is not immortality. It is a signal that serious capital is moving from software into aging itself.
Sources:
statnews.com/2026/05/22/retr…
retro.bio/blog/fundraise-202…
12
Jun 8
AI biology infrastructure signal
QIAGEN is integrating NVIDIA BioNeMo with curated bioinformatics knowledge bases.
Plain English: AI drug discovery needs more than models. It needs trusted disease maps, target biology, and biomarker context.
That is how lab data starts moving toward medicine.
Source:
corporate.qiagen.com/English…
11
Jun 8
Longevity is moving from idea to clinic.
NewLimit raised $435M and says its first aging-reprogramming medicine is headed toward human trials next year.
Plain English: this is not “reverse aging” in people yet. The signal is that cell-age reprogramming is becoming a serious drug-development program, starting with liver cells.
Source:
blog.newlimit.com/p/newlimit…
24
Jun 8
AI x cancer cell therapy signal
Waypoint Bio raised $20M to move AI-designed CAR T programs for solid tumors toward the clinic.
Plain English: the hard part is not making AI generate biology ideas. It is proving which designs survive real tumor environments.
For cancer and healthspan, that feedback loop matters: AI design spatial biology clinical readouts.
Source:
businesswire.com/news/home/2…
22
Jun 7
Programmable biology signal
Base editing has now been tested in human embryos to change single DNA letters linked to disease risk.
Plain English: this is not ready for clinical use, and embryo editing remains ethically serious.
But it shows the direction: medicine is moving from treating disease after birth toward editing biological risk at the code level.
Source:
nature.com/articles/d41586-0…
16
Jun 7
AI x biology capital signal
The next AI wave may not be another chatbot.
Isomorphic Labs raised $2.1B for AI drug design. Nvidia Lilly are putting up to $1B into an AI drug-discovery lab. NewLimit just raised $435M for cell reprogramming.
Plain English: capital is moving from AI that writes text to AI that tests biology.
Not proof of reverse aging yet. But a serious signal.
isomorphiclabs.com/articles/…
39
Jun 7
AI x clinical trials signal
The FDA is testing real-time clinical trials using AI and data science to monitor safety and efficacy signals faster.
Plain English: this is not a new medicine. It is infrastructure that could shorten the path from promising biology to approved therapy.
For healthspan, faster but safer trials matter.
fda.gov/news-events/press-an…
22
Jun 6
AI x cancer imaging signal
GE HealthCare is expanding nuclear medicine with AI-enabled software, radiopharmaceutical diagnostics and quantitative imaging.
Plain English: this is not a cancer cure. It is infrastructure for seeing disease biology earlier, planning therapy more precisely and tracking response.
That is healthspan work.
gehealthcare.com/en-us/about…
1
67
Jun 6
AI x biomedical discovery signal
ARPA-H launched IGoR, an AI-enabled system to generate and test rigorous biological research faster.
Plain English: not a treatment yet. But better experiment design matters because most healthspan progress still depends on slow, expensive biology.
If AI can reduce failed experiments, therapies can move faster.
hhs.gov/press-room/arpa-h-la…
1
1
23
Jun 6
AI x public health signal
OpenAI's Rosalind Biodefense is not a drug or longevity therapy.
But it matters for healthspan: pandemics and biological threats can erase decades of health progress.
The signal is trusted access: advanced biology AI aimed at detection, response and countermeasure design.
openai.com/index/strengtheni…
15
Jun 6
AI x healthspan signal
Cyclarity reported early human data for UDP-003, an AI-discovered molecule designed to bind and help excrete 7-ketocholesterol, a toxic oxidized cholesterol linked to plaque and age-related disease.
Not proof of plaque reversal yet. But it is a clinical step toward treating damage, not just managing risk.
globenewswire.com/news-relea…
13
Jun 5
AI x drug discovery signal
OpenAI updated GPT-Rosalind for life sciences: stronger reasoning in medicinal chemistry, genomics and quantitative biology, plus agentic coding/tool use.
Plain English: this is not a new therapy. It is infrastructure for researchers to test hypotheses, analyze data and design experiments faster.
openai.com/index/introducing…
90